107496-54-8Relevant articles and documents
A practical synthesis of 3,3-difluorocyclobutane carboxylic acid
Elend, Dirk,Fengas, David,Fray, M. Jonathan
, p. 657 - 662 (2005)
We reported a straightforward, three step synthesis of 3,3- difluorocyclobutane carboxylic acid.
Method for synthesizing 3,3-difluorocyclobutanoic acid
-
Paragraph 0015, (2018/10/19)
The invention provides a method for synthesizing 3,3-difluorocyclobutanoic acid. The method specifically comprises the following steps: taking 3-oxocyclobutane formate as a starting raw material, obtaining 3,3-difluorocyclobutanoic acid through generating difluoro-substituted reaction with a fluorinated reagent BAST, generating saponification hydrolysis with alkali and acidifying to obtain the 3,3-difluorocyclobutanoic acid. The method provided by the invention has the advantages of being short in reaction route, stable and safe in raw material performance, mild in reaction condition and suitable for industrial production.
Multigram Synthesis of C 4/C5 3,3-Difluorocyclobutyl-Substituted Building Blocks
Melnykov, Kostiantyn P.,Granat, Dmitriy S.,Volochnyuk, Dmitriy M.,Ryabukhin, Sergey V.,Grygorenko, Oleksandr O.
, p. 4949 - 4957 (2018/12/13)
An approach for the multigram synthesis of 3,3-difluorocyclobutyl-substituted building blocks (including carboxylic acid, amines, alcohols, azide, trifluoroborate ketone) is described. It is shown that, in most cases, ethyl 3,3-difluorocyclobutanecarboxylate is a convenient common synthetic intermediate to obtain the target derivatives. For preparation of 3,3-difluorocyclobutanol or -cyclobutanone, an alternative pathway via reaction of dichloroketene and tert -butyl or benzyl vinyl ether should be applied.
JAK INHIBITORS
-
Paragraph 0172; 0181, (2018/05/03)
Disclosed is a series of JAK inhibitors, which specifically relates to a compound shown in formula (I) or pharmaceutically acceptable salts thereof.
Novel process for synthesizing 3, 3-difluorocyclobutyric acid
-
Paragraph 0047-0050, (2017/04/20)
The invention provides a novel process for synthesizing 3, 3-difluorocyclobutyric acid. No fluorinating reagent like DAST is used, and the novel process is realized directly through three-step reaction, thereby being low in production cost and suitable for industrial production. The novel process has the advantages that yield is increased, and cost is lowered greatly; strong-acid hydrolysis of cyan is omitted, so that yield is increased, cost is lowered, and 'three wastes' are reduced; hydrogenation condition is changed, and original high-pressure reaction is changed into low-pressure reaction, so that reaction dangerousness is reduced, cost is lowered, and yield is increased.
3,3-gem-difluoro cyclobutanecarboxylic acid industrial preparation method
-
Paragraph 0013, (2016/10/17)
The invention relates to a 3,3-gem-difluoro cyclobutanecarboxylic acid industrial preparation method. The method mainly solves the technical problem of existing preparing methods that the price of the raw material 3-oxo-cyclobutylcarboxylic acid or 3-meth
Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors
-
Page/Page column 337; 338, (2016/03/19)
The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
-
Page/Page column, (2015/03/31)
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
-
Page/Page column, (2015/02/19)
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF
-
Page/Page column 62; 63, (2015/02/19)
Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.